Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients[i] New findings from this investigational study build on the strength of the data for amivantamab in ...

Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneous administration AstraZeneca's Saphnelo (anifrolumab) has ...

Results from a US multicenter study presented at CHEST show e-Lung could have sped up Progressive Pulmonary Fibrosis (PPF) diagnosis by up to 21 monthsCHICAGO, USA and OXFORD, UK October 20th 2025 – ...

Successful inspections maintain 19 years of quality and transparency ~Contract research organisation and scientific consultancy Broughton has successfully hosted inspections by the United Kingdom ...

Adaptyx Biosciences announced today it has raised $14 million in seed financing, bringing total funding to $23 million since inception. The round was led by Interlagos, with significant participation ...

Responding to the government's announcement on results of a major trial using artificial intelligence to support NHS administrative work, Dr Layla McCay, director of policy at the NHS Confederation, ...

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today welcomed a new £6 million investment by GSK plc (LSE/NYSE: GSK) and ViiV Healthcare, the global specialist HIV company ...

DKSH Cambodia partnered with Sihanouk Hospital Center of Hope to provide 150 free breast cancer screenings for women from low-income communities, reinforcing its commitment to advancing equity in ...

Further to its strategy update on 19 June, the Company today announces a set of proposals which seek to maximise value for shareholders and to create a sustainable longer-term structure for all key ...

Kelso Pharma, the high-growth specialty pharmaceuticals business, announces that Italian-based Velit Biopharma, acquired in November 2023, will trade as ‘Kelso Pharma Italy’ from today (21 October ...

Highly experienced hires bring robust operational and technical expertiseMomentum builds at Astraveus following exceptional additions of Jean-Paul Mangeolle, David Newble, and Laurence Riot Lamotte ...

A novel therapy called amivantamab has shown early signs of effectiveness in treating advanced head and neck cancer, offering hope for patients with limited options.The drug targets two cancer growth ...